MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press21010.17650/2782-3202-2025-5-4-48-64SUPPORTING THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИResearch ArticleFerric carboxymaltose in therapy of patients with malignant neoplasms complicated by anemia and iron deficiency. Literature review and clinical observationsЖелеза (III) карбоксимальтозат в терапии пациентов со злокачественными новообразованиями, осложненными анемией и дефицитом железа. Обзор литературы и клинические наблюденияhttps://orcid.org/0000-0001-8443-8816RyabukhinaYulia E.РябухинаЮлия Евгеньевна
Russian Federation
gemonk.yur@mail.ruhttps://orcid.org/0000-0003-1564-424XZeynalovaP. A.ЗейналоваП. А.
Russian Federation

Department of Oncology

кафедра онкологии

gemonk.yur@mail.ruhttps://orcid.org/0000-0001-5038-9307DavydovM. M.ДавыдовМ. М.
Russian Federation

Department of Oncology

кафедра онкологии

gemonk.yur@mail.ruClinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)171220255448641712202517122025Copyright ©; 2025, Ryabukhina Y.E., Zeynalova P.A., Davydov M.M.Copyright ©; 2025, Рябухина Ю.Е., Зейналова П.А., Давыдов М.М.2025Ryabukhina Y.E., Zeynalova P.A., Davydov M.M.Рябухина Ю.Е., Зейналова П.А., Давыдов М.М.https://creativecommons.org/licenses/by/4.0https://mdonco.abvpress.ru/jour/article/view/210

The problem of anemia and iron deficiency in patients with malignant neoplasms is important due to pathogenetic features, necessity of differential diagnosis and consideration of concomitant disorders. Integral evaluation using personalized approach can promote timely correction of iron deficiency. Adverse effects of anemia in the preoperative period of some malignant neoplasms on the prognosis of oncological disease and development of chemotherapy-induced anemia predetermine the use of highly stable ferric carboxymaltose complex aimed at fast replenishment of iron with minimal toxicity which significantly improves patients’ quality of life and treatment adherence. Results of randomized trials, as well as real practice data, showed high efficacy and manageable toxicity profile of ferric carboxymaltose in various clinical situations involving iron deficiency.

The article presents a literature review on the problem of anemia and iron deficiency, its correction in patients with malignant neoplasms. Data from clinical trials demonstrating successful use of ferric carboxymaltose in comorbid patients are presented. The choice of this iron formulation for intravenous administration is made on the basis of personalized approach which allows to significantly improve the quality of life.

Проблема анемии и дефицита железа у пациентов со злокачественными новообразованиями актуальна ввиду особенностей патогенеза, необходимости проведения дифференциальной диагностики, а также целесообразности учета имеющихся сопутствующих заболеваний, совокупная оценка которых с применением персонализированного подхода может способствовать своевременной коррекции дефицита железа. Неблагоприятное влияние анемии, наблюдаемой в предоперационном периоде при ряде злокачественных новообразований, на прогноз онкологического заболевания, а также развитие индуцированной химиотерапией анемии предопределяют применение высокостабильного комплекса железа (III) карбоксимальтозата, действие которого направлено на быстрое восполнение дефицита железа с минимальными явлениями токсичности, что значительно улучшает качество жизни больных и повышает приверженность лечению. Результаты проведенных рандомизированных исследований, а также данные реальной практики показали высокую эффективность и управляемый профиль безопасности железа (III) карбоксимальтозата при использовании в разных клинических ситуациях, сопровождаемых дефицитом железа.

В статье представлен обзор данных литературы об актуальности проблемы анемии и дефицита железа, особенностях их коррекции у больных со злокачественными новообразованиями. Приведены данные клинических наблюдений об успешном применении железа (III) карбоксимальтозата у коморбидных пациентов. Выбор в пользу этой лекарственной формы железа для внутривенного введения сделан на основании персонализированного подхода, что позволило значительно улучшить качество жизни.

iron deficiency anemiaabsolute and functional iron deficiencyiron (III) carboxymaltosatemalignant neoplasmжелезодефицитная анемияабсолютный и функциональный дефицит железажелеза (III) карбоксимальтозатзлокачественное новообразованиеEgorova N.A., Kanatnikova N.V. Iron metabolism in the human body and its hygienic limits for drinking water. Review. Part 1. Gigiena i sanitariya = Hygiene and Sanitation 2020;99(4):412–7. (In Russ.). DOI: 10.47470/0016-9900-2020-99-4-412-417Егорова Н.А., Канатникова Н.В. Железо, его метаболизм в организме человека и гигиеническое нормирование в питьевой воде. Обзор литературы. Часть 1. Гигиена и санитария 2020;99(4):412–7. DOI: 10.33029/0016-9900-2020-99-4-412-417Iron deficiency anemia. Russian clinical guidelines. 2024. (In Russ.).Железодефицитная анемия. Клинические рекомендации РФ. 2024.Anemia in malignant neoplasms. Clinical guidelines. 2024. (In Russ.).Анемия при злокачественных новообразованиях. Клинические рекомендации. 2024.Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012;1823(9):1434–43. DOI: 10.1016/j.bbamcr.2012.01.014Ganz T., Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011;2011:538–42. DOI: 10.1182/asheducation-2011.1.538Koduru P., Abraham B.P. The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. Therap Adv Gastroenterol 2016;9(1):76–85. DOI: 10.1177/1756283X15616577VanderWall K., Daniels-Wells T.R., Penichet M., Lichtenstein A. Iron in multiple myeloma. Crit Rev Oncog 2013;18(5):449–61. DOI: 10.1615/critrevoncog.2013007934Silvestris F., Cafforio P., Tucci M., Dammacco F. Negative regulation of erythroblast maturation by Fas-L (+)/TRAIL (+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002;99(4):1305–13. DOI: 10.1182/blood.v99.4.1305Ganz T., Olbina G., Girelli D. et al. Immunoassay for human serum hepcidin. Blood 2008;112(10):492–7. DOI: 10.1182/blood-2008-02-139915Maes K., Nemeth E., Roodman G.D. et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010;116(18):3635–44. DOI: 10.1182/blood-2010-03-274571Banaszkiewicz M., Małyszko J., Batko K. et al. Evaluating the relationship of GDF-15 with clinical characteristics, cardinal features, and survival in multiple myeloma. Mediators Inflamm 2020;2020:5657864. DOI: 10.1155/2020/5657864Orlova R.V., Gladkov O.A., Kutukova S.I. et al. Anemia. Practical recommendations of RUSSCO, part 2. Zlokachestvenniye opukholy = Malignant tumors 2024;14(3s2):22–31. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-2-01Орлова Р.В., Гладков О.А., Кутукова С.И. и др. Анемия. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2024;14(3s2):22–31. DOI: 10.18027/2224-5057-2024-14-3s2-2-01NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hematopoietic growth factors. Management of cancer- and chemotherapy-induced anemia. Version 1.2025.Metivier F., Marchais S.J., Guerin A.P. et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000;15 Suppl 3:14–8. DOI: 10.1093/oxfordjournals.ndt.a027970Cohen-Solal A., Philip J.L., Picard F. et al. Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Fail 2022;9(2):874–84. DOI: 10.1002/ehf2.13850Fougère B., Puisieux F., Chevalet P. et al. Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study. BMC Geriatr 2024;24(1):112. DOI: 10.1186/s12877-024-04719-6Lam C.S.P., Doehner W., Comin-Colet J. et al. Iron deficiency in chronic heart failure: case-based practical guidance. ESC Heart Fail 2018;5:764–71. DOI: 10.1002/ehf2.12333Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128Anker S.D., Kirwan B.A., van Veldhuisen D.J. et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20(1):125–33. DOI: 10.1002/ejhf.823Ahmed M., Shafiq A., Javaid H. et al. Intravenous iron therapy for heart failure and iron deficiency: an updated meta-analysis of randomized clinical trials. ESC Heart Fail 2025;12(1):43–53. DOI: 10.1002/ehf2.14905Kulnigg S., Stoinov S., Simanenkov V. et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103(5):1182–92. DOI: 10.1111/j.1572-0241.2007.01744.xMacdougall I.C., Bock A.H., Carrera F. et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29(11):2075–84. DOI: 10.1093/ndt/gfu201Shin H.W., Go D.Y., Lee S.W. et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and meta-analysis. Medicine 2021;100(20):e24571. DOI: 10.1097/MD.0000000000024571Evstatiev R., Marteau P., Iqbal T. et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141(3):846–53.e1–2. DOI: 10.1053/j.gastro.2011.06.005Roberts V., Deftereos I., Mahbub B. et al. Anaemia and its impact on colorectal cancer patients: how can we better optimize surgical outcomes? ANZ J Surg 2021;91(5):E280–5. DOI: 10.1111/ans.16774Skorupski C.R., Cheung M.C., Hallet J. et al. Preoperative anemia and iron deficiency in elective gastrointestinal cancer surgery patients. J Surg Oncol 2025;131(4):614–23. DOI: 10.1002/jso.27970Yovino S., Kwok Y., Krasna M. et al. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 2005;62(5):1438–43. DOI: 10.1016/j.ijrobp.2004.12.038Liu Y., Bai Y.P., Zhou Z.F. et al. Preoperative anemia as a prognostic factor in patients with lung cancer: a systematic review and meta-analysis of epidemiological studies. J Cancer 2019;10(9):2047–56. DOI: 10.7150/jca.29410Wilson M.J., Dekker J.W.T., Harlaar J.J. et al. The role of preoperative iron deficiency in colorectal cancer patients: prevalence and treatment. Int J Colorectal Dis 2017;32(11):1617–24. DOI: 10.1007/s00384-017-2898-1Aktaş B.Y., Ata E.B., Çeşmeci E. et al. Seven-year single-center experience of the efficacy and safety of ferric carboxymaltose in cancer patients with iron-deficiency anemia. Curr Oncol 2023;30(11):9689–700. DOI: 10.3390/curroncol30110703Calleja J.L., Delgado S., del Val A. et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis 2016;31(3):543–51. DOI: 10.1007/s00384-015-2461-xKeeler B.D., Simpson J.A., Tselepis C. et al. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis 2014;16(10):794–800. DOI: 10.1111/codi.12683Huang J., Feldman A.S., Dong L. et al. Preoperative anemia as an independent prognostic indicator of papillary renal cell carcinoma. Clin Genitourin Cancer 2015;13(5):e353–60. DOI: 10.1016/j.clgc.2015.04.014Tokunaga R., Nakagawa S., Miyamoto Y. et al. The impact of preoperative anaemia and anaemic subtype on patient outcome in colorectal cancer. Colorectal Dis 2019;21(1):100–9. DOI: 10.1111/codi.14425Laso-Morales M.J., Vives R., Bisbe E. et al. Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: a randomised controlled trial. Blood Transfus 2022;20(4):310–8. DOI: 10.2450/2021.0157-21Keeler B.D., Simpson J.A., Ng O. et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg 2017;104(3):214–21. DOI: 10.1002/bjs.10328Talboom K., Borstlap W.A.A., Roodbeen S.X. et al. Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open label, randomised, controlled trial. Lancet Haematol 2023;10(4):e250–60. DOI: 10.1016/S2352-3026(22)00402-1Steinmetz T., Tschechne B., Harlin O. et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24(2):475–82. DOI: 10.1093/annonc/mds338Makharadze T., Boccia R., Krupa A. et al. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, placebo-controlled study (IRON-CLAD). Am J Hematol 2021;96(12):1639–46. DOI: 10.1002/ajh.26376Marinho J., Leão I., Custódio S. et al. Ferric carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion. Sci Rep 2019;9(1):20410. DOI: 10.1038/s41598-019-56999-3Moore R.A., Gaskell H., Rose P., Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011;11:4. DOI: 10.1186/1471-2326-11-4Hussain I., Bhoyroo J., Butcher A. et al. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia 2013;2013:169107. DOI: 10.1155/2013/169107Dave C.V., Brittenham G.M., Carson J.L., Setoguchi S. Risks for anaphylaxis with intravenous iron formulations: a retrospective cohort study. Ann Intern Med 2022;175(5):656–64. DOI: 10.7326/M21-4009Trumbo H., Kaluza K., Numan S., Goodnough L.G. Frequency and associated costs of anaphylaxis- and hypersensitivity-related adverse events for intravenous iron products in the USA: an analysis using the US food and drug administration adverse event reporting system. Drug Saf 2021;44(1):107–19. DOI: 10.1007/s40264-020-01022-2Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009; 23(1):11–6.Instructions for medical use of Ferinject® pharmaceutical (solution for intravenous administration 50 mg/mL). No. LSR-008848. (In Russ.).Инструкция по медицинскому применению лекарственного препарата Феринжект® (раствор для внутривенного введения 50 мг/мл). № ЛСР-008848.Geisser P., Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011;3(1):12–33. DOI: 10.3390/pharmaceutics3010012Toledano A., Luporsi E., Morere J.F. et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 2016;24(1):67–75. DOI: 10.1007/s00520-015-2728-3Thomas M.C., Tsalamandris C., Macisaac R., Jerums G. Functional erythropoietin deficiency in patients with type 2 diabetes and anaemia. Diabet Med 2006;23(5):502–9. DOI: 10.1111/j.1464-5491.2006.01829.xMeliš P., Berkovic M.C. Anemia risk and mitigation strategies in type 2 diabetic patients: the role of novel antidiabetic agents. World J Diabetes 2025;16(5):105549. DOI: 10.4239/wjd.v16.i5.105549New J.P., Aung T., Baker P.G. et al. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study. Diabet Med 2008;25(5):564–9. DOI: 10.1111/j.1464-5491.2008.02424.xVlagopoulos P.T., Tighiouart H., Weiner D.E. et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16(11):3403–10. DOI: 10.1681/ASN.2005030226Idris I., Tohid H., Muhammad N.A. et al. Anaemia among primary care patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD): a multicentred cross-sectional study. BMJ Open 2018;8(12):e025125. DOI: 10.1136/bmjopen-2018–025125Liu Y., Desai P., Nadeem O. et al. Precursor hematologic conditions: diagnosis, risk stratification, clinical implications, and management. Am Soc Clin Oncol Educ Book 2025;45(3):e473650. DOI: 10.1200/EDBK-25-473650Kosydar S., Archibald W.J., Hampel P.J. et al. The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis. Br J Haematol 2025;207(3):860–8. DOI: 10.1111/bjh.70009Serafin A., Sant’Antonio E., Mavilia F. et al. Monoclonal B-cell lymphocytosis: the silent clone the haematologists should not neglect. Hematol Oncol 2025;43 Suppl 2(Suppl 2):e70084. DOI: 10.1002/hon.70084Ye Z., Long M., Li L. Serum iron levels predict mortality risk in hypertensive patients: a prospective cohort study. Nutr Metab Cardiovasc Dis 2025;35(6):104017. DOI: 10.1016/j.numecd.2025.104017Anker S.D., Karakas M., Mentz R.J. et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med 2025;31(8):2640–6. DOI: 10.1038/s41591-025-03671-1Corradi F., Masini G., Bucciarelli T., De Caterina R. Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives. Cardiovasc Res 2023;119(14):2405–20. DOI: 10.1093/cvr/cvad146Khastieva D.R., Khasanov N.R. Iron deficiency in patients with coronary artery disease. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology 2022;27(4S):4962. (In Russ.). DOI: 10.15829/1560-4071-2022-4962Хастиева Д.Р., Хасанов Н.Р. Дефицит железа у больных с ишемической болезнью сердца. Российский кардиологический журнал 2022;27(S4):4962. DOI: 10.15829/1560-4071-2022-4962Taherifard E., Taherifard E., Movahed H., Mousavi M.R. Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. Hematology 2021;26(1):225–39. DOI: 10.1080/16078454.2021.1881225Semenenkova A.N., Shtonda M.V., Pristrom M.S., Semenenkov I.I. Liver damage in coronavirus infection. Meditsinskie novosti = Medical News 2022;7:12–6. (In Russ.).Семененкова А.Н., Штонда М.В., Пристром М.С., Семененков И.И. Поражение печени при коронавирусной инфекции. Медицинские новости 2022;7:12–6.Abdulganieva D.I., Akhberova D.R. Clinical picture, diagnostics and treatment of autoimmune hepatitis. Doctor.Ru 2019;3(158):27–32. (In Russ.). DOI: 10.31550/1727-2378-2019-158-3-27-32Абдулганиева Д.И., Акберова Д.Р. Клиника, диагностика и лечение аутоиммунного гепатита. Доктор.Ру 2019;3(158):27–32. DOI: 10.31550/1727–2378-2019-158-3-27-32